ClinicalTrials.gg
CompletedNCT02918019Updated Dec 28, 2022Results posted

A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma

A Phase 2 interventional study of MSTT1041A and Placebo in Asthma, sponsored by Hoffmann-La Roche. Completed at 138 sites in 15 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-28.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Asthma by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Asthma · Hoffmann-La Roche.

Enrollment
7th of 35
517 · median 135
Started
2016
with 1 other
Phase 2
19 of 41
none open now
Registered
38th of 41
by date

Among the 41 studies in Asthma by Hoffmann-La Roche, this one is the 7th largest by enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2016, is one of 19 in phase 2, and was the 38th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 41 studies in Asthma by Hoffmann-La Roche is open now. The open studies under Asthma, anywhere →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies in Asthma by Hoffmann-La Roche as a file.
02

Study summary

This is a Phase IIb, randomized, placebo-controlled, double-blind, multicenter, multi-arm study which will evaluate efficacy, safety, and pharmacokinetic of MSTT1041A compared with placebo as add-on therapy in participants with severe, uncontrolled asthma who are receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one of the following additional controller medications: long-acting beta-agonists (LABA), leukotriene modifier (LTM), long-acting muscarinic antagonist (LAMA), or long-acting theophylline preparation. The total duration of this study for each participant is approximately 70 weeks including screening, run-in, treatment, and follow-up.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 18 to 38 kilogram/square meter (kg/m\^2) and weight >= 40 kg at screening
  • Documented physician-diagnosed asthma
  • On high dose inhaled (ICS) therapy plus at least one additional allowed controller medication
  • (FEV1) of 40% to 80% of predicted
  • Evidence of uncontrolled asthma
  • Use of measures

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of mimics of asthma
  • Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma overlap syndrome, or bronchiolitis, as determined by the investigator
  • Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A
  • Recent history of smoking
  • History or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, have an impact on the study results
  • Asthma exacerbation within 4 weeks prior to screening
  • Intubation for respiratory failure due to asthma within 12 months prior to screening
  • Comorbid conditions that may interfere with evaluation of medicinal product
  • Known sensitivity to any of the active substances or their to be administered during dosing
  • Positive pregnancy test
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
517 participants (actual)

Study arms

  • Experimental
    MSTT1041A 210 mg

    Participants will receive MSTT1041A 210 milligrams (mg), subcutaneously every 4 weeks from randomization through Week 50.

    Drug: MSTT1041A

  • Experimental
    MSTT1041A 490 mg

    Participants will receive MSTT1041A 490 mg, subcutaneously every 4 weeks from randomization through Week 50.

    Drug: MSTT1041A

  • Experimental
    MSTT1041A 70 mg

    Participants will receive MSTT1041A 70 mg, subcutaneously every 4 weeks from randomization through Week 50.

    Drug: MSTT1041A

  • Placebo comparator
    Placebo

    Participants will receive placebo matched with MSTT1041A, subcutaneously every 4 weeks from randomization through Week 50.

    Drug: Placebo

Interventions

  • MSTT1041A will be administered as subcutaneous injections.

    Also known as: RO7187807

  • DrugPlacebo

    Placebo matched with MSTT1041A.

06

What researchers measure

Primary outcomes

  1. Reduction in Rate of Asthma Exacerbations

    Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Adjusted rates for the overall mITT population (all participants that received at least one dose of study drug) were estimated using Poisson regression and adjusted for blood eosinophil level at the first visit, the number of asthma exacerbations requiring systemic corticosteroids in the 12 months prior to study entry, the total daily ICS dose at the first visit, and geographic region, with patient time at risk used as an offset term.

    Time frame: Baseline to Week 54

Secondary outcomes

  1. Absolute Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 measures how much air a person can exhale during the first second of a forced breath. Adjusted means are reported.

    Time frame: Baseline to Week 54

  2. Time to First Asthma Exacerbation

    Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days.

    Time frame: 52 Weeks

  3. Achievement in Improvement in Standardized Asthma Quality-of-Life Questionnaire (AQLQ(S)) Score

    The AQLQ measures the functional problems (physical, emotional, social, and occupational) most troublesome to adults (17-70 years) with asthma. There are 32 questions in 4 domains - symptoms, activity limitation, emotional function, and environmental stimuli - scored on a 7 point scale, with 7= no impairment and 1= severely impaired. For this study, improvement achievement was defined as an increase of at least 0.5 points from baseline to week 54. Adjusted rates are reported.

    Time frame: Week 54

  4. Absolute Change in Patient-Reported Use of Short-Acting Rescue Therapy

    Adjusted mean values are all equal to zero.

    Time frame: Baseline to Week 54

  5. Proportion of Weeks Without Patient-Reported Asthma-Related Nighttime Awakenings

    The adjusted mean proportion of weeks without a nighttime awakening from baseline through week 54 are reported. The proportion of weeks is expressed as a percentage.

    Time frame: Baseline through Week 54

  6. Absolute Change in Patient-Reported Daytime Asthma Symptom Severity as Measured by the Asthma Daily Symptom Diary (ADSD)

    The ADSD is a 6-item daily measure of asthma symptom severity that assesses three core categories of asthma symptoms: breathing symptoms, chest symptoms, and cough. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (no symptoms) to 10 (the worst symptoms imaginable). Adjusted means are reported.

    Time frame: Baseline to Week 54

  7. Percentage of Participants With Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline to Week 54

  8. Percentage of Participants With Anti-Drug Antibodies (ADAs)

    The prevalence of ADAs at baseline was defined as the proportion of the evaluable participant population in a study that is ADA positive at baseline.

    Time frame: Baseline

  9. Serum Concentration of Astegolimab (MSTT1041A)

    Time frame: Weeks 26 and 54

  10. Percentage of Participants With Treatment-Emergent ADAs

    The incidence of ADAs at post-baseline timepoints was defined as the proportion of the study population found to have developed treatment-emergent ADAs.

    Time frame: From baseline to the first appearance of ADAs at any point post-baseline (up to Week 54)

07

Results

Posted Dec 28, 2022

Participant flow

Adult participants with severe, uncontrolled asthma receiving medium- or high-dose inhaled corticosteroid (ICS) therapy and at least one additional controller medication.

Participant flow — Overall Study
MilestonePlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Started127127126122
Completed121117117113
Not completed61099
Withdrew: Death0010
Withdrew: Lost to follow-up1101
Withdrew: Principal investigator request0001
Withdrew: Physician decision1320
Withdrew: Protocol deviation1102
Withdrew: Withdrawal by subject3464
Withdrew: Adverse event0101

Outcome measures

SecondaryAbsolute Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)

FEV1 measures how much air a person can exhale during the first second of a forced breath. Adjusted means are reported.

Time frame:
Baseline to Week 54
Reported as:
Mean · Milliliters (mL)
Absolute Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Milliliters (mL)PlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Absolute Change in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)107 ± 47130 ± 70154 ± 93172 ± 110
SecondaryTime to First Asthma Exacerbation

Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days.

Time frame:
52 Weeks
Reported as:
Median · Weeks
Time to First Asthma Exacerbation
WeeksPlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Time to First Asthma ExacerbationNA (46.6 to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryAchievement in Improvement in Standardized Asthma Quality-of-Life Questionnaire (AQLQ(S)) Score

The AQLQ measures the functional problems (physical, emotional, social, and occupational) most troublesome to adults (17-70 years) with asthma. There are 32 questions in 4 domains - symptoms, activity limitation, emotional function, and environmental stimuli - scored on a 7 point scale, with 7= no impairment and 1= severely impaired. For this study, improvement achievement was defined as an increase of at least 0.5 points from baseline to week 54. Adjusted rates are reported.

Time frame:
Week 54
Reported as:
Number · Percentage
Achievement in Improvement in Standardized Asthma Quality-of-Life Questionnaire (AQLQ(S)) Score
PercentagePlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Week 54 - Responder55.364.861.368.9
Week 54 - Non-responder44.735.238.731.1
SecondaryAbsolute Change in Patient-Reported Use of Short-Acting Rescue Therapy

Adjusted mean values are all equal to zero.

Time frame:
Baseline to Week 54
Reported as:
Mean · Usage
Absolute Change in Patient-Reported Use of Short-Acting Rescue Therapy
UsagePlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Absolute Change in Patient-Reported Use of Short-Acting Rescue Therapy0 (0 to 0)0 (0 to 0)0 (0 to 0)0 (0 to 0)
SecondaryProportion of Weeks Without Patient-Reported Asthma-Related Nighttime Awakenings

The adjusted mean proportion of weeks without a nighttime awakening from baseline through week 54 are reported. The proportion of weeks is expressed as a percentage.

Time frame:
Baseline through Week 54
Reported as:
Mean · Percentage of weeks
Proportion of Weeks Without Patient-Reported Asthma-Related Nighttime Awakenings
Percentage of weeksPlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Proportion of Weeks Without Patient-Reported Asthma-Related Nighttime Awakenings0.4 (-0.7 to 1.5)0.4 (-0.7 to 1.5)0.3 (-0.7 to 1.3)0.3 (-0.7 to 1.3)
SecondaryAbsolute Change in Patient-Reported Daytime Asthma Symptom Severity as Measured by the Asthma Daily Symptom Diary (ADSD)

The ADSD is a 6-item daily measure of asthma symptom severity that assesses three core categories of asthma symptoms: breathing symptoms, chest symptoms, and cough. Symptoms are rated at their worst using an 11-point numeric rating scale ranging from 0 (no symptoms) to 10 (the worst symptoms imaginable). Adjusted means are reported.

Time frame:
Baseline to Week 54
Reported as:
Mean · Scores on a scale
Absolute Change in Patient-Reported Daytime Asthma Symptom Severity as Measured by the Asthma Daily Symptom Diary (ADSD)
Scores on a scalePlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Absolute Change in Patient-Reported Daytime Asthma Symptom Severity as Measured by the Asthma Daily Symptom Diary (ADSD)-1 (-2 to -1)-2 (-2 to -1)-1 (-2 to -1)-1 (-2 to -1)
SecondaryPercentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline to Week 54
Reported as:
Number · Percentage
Percentage of Participants With Adverse Events
PercentagePlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Percentage of Participants With Adverse Events77.270.972.272.1
SecondaryPercentage of Participants With Anti-Drug Antibodies (ADAs)

The prevalence of ADAs at baseline was defined as the proportion of the evaluable participant population in a study that is ADA positive at baseline.

Time frame:
Baseline
Reported as:
Number · Percentage
Percentage of Participants With Anti-Drug Antibodies (ADAs)
PercentagePlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Percentage of Participants With Anti-Drug Antibodies (ADAs)5.60.81.61.7
SecondarySerum Concentration of Astegolimab (MSTT1041A)
Time frame:
Weeks 26 and 54
Reported as:
Geometric mean · ug/mL
Serum Concentration of Astegolimab (MSTT1041A)
ug/mLAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Week 26 pre-dose4.75 ± 123.316.9 ± 167.340.5 ± 161.2
Week 544.47 ± 144.117.4 ± 155.438.7 ± 226.4
SecondaryPercentage of Participants With Treatment-Emergent ADAs

The incidence of ADAs at post-baseline timepoints was defined as the proportion of the study population found to have developed treatment-emergent ADAs.

Time frame:
From baseline to the first appearance of ADAs at any point post-baseline (up to Week 54)
Reported as:
Number · Percentage
Percentage of Participants With Treatment-Emergent ADAs
PercentagePlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Percentage of Participants With Treatment-Emergent ADAs7.19.68.93.3
PrimaryReduction in Rate of Asthma Exacerbations

Asthma exacerbation was defined as new or increased asthma symptoms (wheezing, coughing, dyspnea, chest tightness, and/or nighttime awakenings due to these symptoms) that result in one or both of the following: Hospitalization or emergency department visit with administration of systemic corticosteroid treatment; Treatment with systemic corticosteroids for at least 3 days, or a long-acting depot corticosteroid preparation with a therapeutic effectiveness of at least 3 days. Adjusted rates for the overall mITT population (all participants that received at least one dose of study drug) were estimated using Poisson regression and adjusted for blood eosinophil level at the first visit, the number of asthma exacerbations requiring systemic corticosteroids in the 12 months prior to study entry, the total daily ICS dose at the first visit, and geographic region, with patient time at risk used as an offset term.

Time frame:
Baseline to Week 54
Reported as:
Number · Number of asthma exacerbations per year
Reduction in Rate of Asthma Exacerbations
Number of asthma exacerbations per yearPlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
Reduction in Rate of Asthma Exacerbations0.740.470.580.42
Statistical analysis
  • Astegolimab (MSTT1041A) 490mg · Poisson regression · p = 0.0049 · Rate ratio: 0.57 · 95% CI 0.39 to 0.84
  • Astegolimab (MSTT1041A) 210mg · Poisson regression · p = 0.1838 · Rate ratio: 0.78 · 95% CI 0.54 to 1.12
  • Astegolimab (MSTT1041A) 70mg · Poisson regression · p = 0.0144 · Rate ratio: 0.63 · 95% CI 0.44 to 0.91

Adverse events

Collected over Baseline to Week 54. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/127 (0%)8/127 (6.3%)76/127 (59.8%)
Astegolimab (MSTT1041A) 70mg0/127 (0%)14/127 (11%)65/127 (51.2%)
Astegolimab (MSTT1041A) 210mg1/126 (0.8%)9/126 (7.1%)75/126 (59.5%)
Astegolimab (MSTT1041A) 490mg1/122 (0.8%)6/122 (4.9%)68/122 (55.7%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
AsthmaRespiratory, thoracic and mediastinal disorders2/1272/1274/1261/122
Atrial fibrillationCardiac disorders0/1270/1272/1260/122
OsteoarthritisMusculoskeletal and connective tissue disorders0/1272/1270/1260/122
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1272/1270/1260/122
CataractEye disorders0/1270/1270/1261/122
DeathGeneral disorders0/1270/1271/1261/122
CellulitisInfections and infestations0/1270/1270/1261/122
PneumoniaInfections and infestations1/1271/1270/1261/122
Vocal cord disorderRespiratory, thoracic and mediastinal disorders0/1270/1270/1261/122
Hypertensive crisisVascular disorders0/1270/1270/1261/122
Most frequent other events
Most frequent other events
EventPlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mg
AsthmaRespiratory, thoracic and mediastinal disorders58/12742/12753/12639/122
NasopharyngitisInfections and infestations13/12712/12721/12616/122
HeadacheNervous system disorders6/1278/1276/12614/122
Upper respiratory tract infectionInfections and infestations12/1279/1278/1266/122
Injection site reactionGeneral disorders1/12710/1278/1266/122
InfluenzaInfections and infestations5/1272/1272/1267/122
RhinitisInfections and infestations7/1277/1273/1262/122
SinusitisInfections and infestations3/1277/1273/1265/122
ArthralgiaMusculoskeletal and connective tissue disorders2/1277/1274/1264/122
Back painMusculoskeletal and connective tissue disorders7/1275/1275/1264/122

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mgTotal
Mean51.4 ± 12.252.4 ± 11.952.5 ± 12.051.4 ± 12.051.9 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mgTotal
Female82819079332
Male45463643170
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mgTotal
Hispanic or Latino1819151466
Not Hispanic or Latino109108110108435
Unknown or Not Reported00101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAstegolimab (MSTT1041A) 70mgAstegolimab (MSTT1041A) 210mgAstegolimab (MSTT1041A) 490mgTotal
American Indian or Alaska Native558422
Asian644923
Native Hawaiian or Other Pacific Islander00000
Black or African American896629
White107105108102422
More than one race14016
Unknown or Not Reported00000
08

Study locations

138 sites
  • Alabama Allergy & Asthma
    Birmingham, Alabama 35209, United States
  • Del Sol Research Management
    Tucson, Arizona 85710, United States
  • Kern Allergy Med Clinic, Inc.
    Bakersfield, California 93301, United States
  • Allergy & Asthma Care Center of Southern California
    Long Beach, California 90808, United States
  • CA Allergy & Asthma Med Grp; Medical Group, Inc.
    Los Angeles, California 90025, United States
  • Jonathan Corren MD, Inc.
    Los Angeles, California 90025, United States
  • Office of Robert N Wolfe MD
    Los Angeles, California 90048, United States
  • Advances in Medicine
    Rancho Mirage, California 92270, United States
  • Allergy & Asthma Consultants
    Redwood City, California 94063, United States
  • Bensch Research Associates
    Stockton, California 95207, United States
  • Allergy and Asthma Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Asthma & Allergy; Associates, P.C.
    Colorado Springs, Colorado 80907, United States
  • Western States Clinical Research, Inc
    Wheat Ridge, Colorado 80033, United States
  • Yale University School Of Medicine
    New Haven, Connecticut 06519, United States
  • Emerald Coast Research Associates
    Panama City, Florida 32405, United States
  • Florida Premier Research Institute
    Winter Park, Florida 32789, United States
  • Atlanta Allergy & Asth Clin PC
    Stockbridge, Georgia 30281, United States
  • Asthma & Allergy of Idaho
    Twin Falls, Idaho 83301, United States
  • Asthma, Allergy & Sinus Center
    Baltimore, Maryland 21236, United States
  • Chesapeake Clinical Research Inc - CRN
    Baltimore, Maryland 21236, United States
  • Genesis Clinical Research & Consulting, LLC
    Fall River, Massachusetts 02720, United States
  • Infinity Medical Research Inc
    North Dartmouth, Massachusetts 02747, United States
  • Midwest Clinical Research LLC
    Saint Louis, Missouri 63141, United States
  • The Allergy and Asthma Center
    Bellevue, Nebraska 68123, United States
  • Montefiore Medical Center
    Bronx, New York 10461, United States
  • American Health Research Inc.
    Charlotte, North Carolina 28277, United States
  • Allergy & Respiratory Center
    Canton, Ohio 44718, United States
  • Integrity People Services Research Company
    Oklahoma City, Oklahoma 73103, United States
  • Vital Prospects Clin Res Pc
    Tulsa, Oklahoma 74136, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Asthma & Allergy Physicians of Rhode Island Clinical Research Institute (AAPRI CRI)
    Warwick, Rhode Island 02865, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29303, United States
  • Clinical Research Solutions PC
    Knoxville, Tennessee 37920, United States
  • Meharry Medical College; Clinical Trials Office
    Nashville, Tennessee 37208, United States
  • TTS Research
    Boerne, Texas 78006, United States
  • Elliot J. Ginchansky, MD, PA
    Dallas, Texas 75230, United States
  • Pioneer Research Solutions
    Houston, Texas 077099, United States
  • Metroplex Pulmonology & Sleep Center
    McKinney, Texas 75069, United States
  • Allergy & Asthma Research Center
    San Antonio, Texas 78229, United States
  • Allergy Associates of Utah
    Murray, Utah 84107, United States
  • Commonwealth Clinical Research Specialists
    Richmond, Virginia 23226, United States
  • Washington Univ School of Med
    Seattle, Washington 98195, United States
  • Fundacion Cidea
    Buenos Aires, C1121ABE, Argentina
  • INAER
    Ciudad Autónoma de Buenos Aires, C1425BEN, Argentina
  • INSARES
    Mendoza, Mendoza City, M5500CCG, Argentina
  • Fundacion Scherbovsky
    Mendoza, M5500AYB, Argentina
  • Centro Respiratorio Quilmes
    Quilmes, B1878FNR, Argentina
  • Instituto Especialidades de la Salud Rosario
    Rosario, S2000DBS, Argentina
  • Instituto de Diagnóstico ABC; Servicio de Investigación de Patologías Alérgicas
    Rosario, S2000JKE, Argentina
  • Centro Modelo de Cardiologia
    San Miguel de Tucuman, 4000, Argentina
  • Investigaciones en Patologias Respiratorias
    San Miguel de Tucuman, T4000IAR, Argentina
  • CEMER Centro Medico de Enfermedades Respiratorias
    Vicente López, B1602DQD, Argentina
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • Private Practice Dr Jean Benoit Martinot
    Erpent, 5101, Belgium
  • Military Medical Academy HBAT
    Pleven, 5800, Bulgaria
  • SHATPPD Dr. Dimitar Gramatikov, Ruse Ltd.
    Ruse, 7002, Bulgaria
  • Medical Centre Mladost Med 1 EOOD
    Sofia, 1000, Bulgaria
  • First MHAT; Clinic of Neurology
    Sofia, 1142, Bulgaria
  • Fifth MHAT - Sofia EAD
    Sofia, 1233, Bulgaria
  • National Multiprofile Hospital Tsar Boris III
    Sofia, 1233, Bulgaria
  • Specialised Hospital for Active Treatment of Pulmonary Deseases "Sv. Sofia", Third Clinic for Non-Sp
    Sofia, 1431, Bulgaria
  • Uni. Multiprofile Hosp. for Active Treatment-Aleksandrovska
    Sofia, 1431, Bulgaria
  • Medical Center N.I. Pirogov EOOD
    Sofia, 1606, Bulgaria
  • Alitera - Med - Medical Center EOOD
    Sofia, 1618, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, 6000, Bulgaria
  • Medical Center Tara OOD
    Veliko Tarnovo, 5000, Bulgaria
  • Aggarwal and Associates
    Brampton, Ontario L6T 0G1, Canada
  • Cheema Research
    Mississauga, Ontario L5A 3V4, Canada
  • Inspiration Research
    Toronto, Ontario M5T 3A9, Canada
  • Anil Dhar Professional Medicine Corporation
    Windsor, Ontario N8X 5A6, Canada
  • C.I.C. Mauricie
    Trois-Rivières, Quebec G8T 7A1, Canada
  • MediTrial s.r.o.
    Jindřichův Hradec, 377 01, Czechia
  • EUC Klinika Ostrava a.s.
    Ostrava-Poruba, 708 00, Czechia
  • Ordinace pro tuberkulozu a respiracni nemoci
    Strakonice, 38601, Czechia
  • KASMED s.r.o.
    Tabor, 390 01, Czechia
  • Alergologie Teplice, s.r.o.
    Teplice, 415 01, Czechia
  • Pneumologisches Forschungsinstitut Hohegeest
    Geesthacht, 21502, Germany
  • POIS Leipzig Gbr
    Leipzig, 04357, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Medizinische Klinik, Pneumologie
    Mainz, 55131, Germany
  • Universitatsklinikum Munster
    Münster, 48149, Germany
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Greenlane Clinical Centre
    Auckland, 1051, New Zealand
  • Medical Research Institute of New Zealand
    Wellington, 6021, New Zealand
  • Clinica Internacional
    Lima, Lima 1, Peru
  • Abk Reuma Srl- Medicentro
    Lima, Lima 21, Peru
  • Clinica Ricardo Palma; THORAX
    Lima, Lima 27, Peru
  • Instituto Peruano de Investigacion en Ciencias Medicas
    Lima, Lima 32, Peru
  • Clinica San Borja
    Lima, Lima 41, Peru
  • Hospital Santa Rosa Piura
    Piura, 20001, Peru
  • Centrum Medycyny Oddechowej Robert M. Mróz
    Bialystok, 15-003, Poland
  • Centrum Medyczne ALL-MED
    Krakow, 30-033, Poland
  • Malopolskie Centrum Alergologii
    Krakow, 31-624, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej Centrum Medyczne ProMiMed sp z o.o. sp.k.
    Kraków, 31-637, Poland
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi
    Lodz, 90-153, Poland
  • Specjalistyczna Poradnia Pulmonologiczna
    Ostrow Wielkopolski, 63-400, Poland
  • Przedsiebiorstwo Podmiotu Leczniczego Poradnie Specjalistyczne MAGMED
    Radom, 26-600, Poland
  • ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o
    Tarnow, 33-100, Poland

Showing the first 100 of 138 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, Theess W, Yang X, Staton TL, Choy DF, Fong A, Dash A, Dolton M, Pappu R, Brightling CE. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-798. doi: 10.1016/j.jaci.2021.03.044. Epub 2021 Apr 16. PubMed 33872652 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Apr 2019, 30 months.

Results were first posted in Dec 2022, 3 years 8 months after primary completion. A results delay was requested in Apr 2020.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 30 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Sep 28, 2016
StartActual
Sep 20, 2016
Primary completionActual
Apr 5, 2019
CompletionActual
Jul 26, 2019
Results delay requested
Apr 2, 2020
Results first posted
Dec 28, 2022
Last update
Dec 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02918019
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 28, 2016
Start date
Sep 20, 2016
Primary completion
Apr 5, 2019
Completion
Jul 26, 2019
Results posted
Dec 28, 2022
Last update
Dec 28, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Astegolimab

Start the discussion